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Abstract
Background: Preclinical and observational studies raise the concern about the safety of insulin glargine in terms of cancer
initiation and promotion. This study is designed to examine cancer incidence associated with use of insulin glargine vs.
intermediate/long-acting human insulin (HI).
Methodology: A retrospective cohort study using the Taiwan National Health Insurance claims database was conducted to
identify adult patients with type 2 diabetes mellitus and without a history of cancer who initiated insulin glargine
(n=10,190) or intermediate/long-acting HI (n=49,253) during 2004–2007. Exclusive users were followed from the date of
insulin initiation to the earliest of cancer diagnosis, death, disenrollment, or December 31 2007. We estimated adjusted
hazard ratios and 95% confidence intervals (CIs) with Cox proportional hazards models adjusting for baseline propensity
score.
Findings: The incidence rate of all cancer per 1,000 person-years was 13.8 for insulin glargine initiators (179 cases) and 16.0
for intermediate/long-acting HI initiators (1,445 cases) during an average follow-up of 2 years. No significant difference in
overall cancer risk between insulin glargine initiators and HI initiators was found. For men, however, the adjusted hazard
ratio of insulin glargine use as compared with intermediate/long-acting HI was 2.15 (95% CI 1.01–4.59) for pancreatic cancer,
and 2.42 (95% CI 1.50–8.40) for prostate cancer. The increased risk was not observed among women.
Conclusions: Insulin glargine use did not increase the risk of overall cancer incidence as compared with HI. The positive
associations with pancreatic and prostate cancer need further evaluation and validation.
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Introduction
During the past decades, long-acting insulin preparations have
become widely used as a basal insulin supplement for diabetic
patients due to their stable action and lower risk of nocturnal
hypoglycemia. However, modification of amino acids on the
insulin chain for these new insulin analogues may not only change
metabolic properties but also alter their mitogenic effects, probably
through prolonged binding to insulin receptor or by increased
cross-reactivity with IGF-1 receptor [1]. Several studies showed
that as compared with human insulin, insulin glargine – a long-
acting insulin analogue – might substantially increase cellular
proliferative potential, while the mitogenic potency of the other
insulin analogues, including insulin detemir, were similar to or
lower than human insulin [2]. In addition, it has been shown that
insulin glargine, but not human insulin, increases resistance to
apoptosis in several tumor cell lines including colorectal, breast,
and prostate cancers [3]. These preclinical studies raise the
concern about a potential link between insulin glargine and cancer
initiation and promotion.
While one open-label randomized trial and a combined analysis
of 31 randomized controlled trials (mostly of 6-month duration)
found no difference in cancer occurrence between insulin glargine
and comparative groups (mostly neutral protamine Hagedorn
insulin) [4,5], observational studies analyzing large electronic
healthcare databases or diabetes registry showed conflicting results
[6–10]. A cohort study from Germany reported that the risk of
overall cancer increased with dose for any type of insulin. The
hazard ratio for overall insulin glargine use as compared with
human insulin was 0.86. However, at doses greater than 40 IU,
users of insulin glargine but not insulin aspart and insulin lispro
had a higher risk than individuals using human insulin [6]. Similar
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showing that the incidence of overall cancer was associated with a
daily dose of insulin glargine $0.3 IU/kg but not for human
insulin or other analogues [7]. Additionally, two studies in Sweden
and Scotland suggested that women using insulin glargine alone
had a significantly higher risk of breast cancer as compared with
users of other types of insulin, whereas this increased risk was not
observed among those who received insulin glargine in combina-
tion with other insulin [8,9]. In contrast, a UK study found that
despite a higher risk of overall cancer among diabetic patients
receiving insulin or sulfonylurea compared to those using
metformin, the risk was similar for different insulin formulations
at the doses used in clinical practice [10].
Residual confounding, reverse causation, selection or detection
biases might have influenced the validity of these studies [11,12].
In this study, we examined whether cancer incidence was
associated with the use of insulin glargine compared to
intermediate/long-acting human insulin (HI) using the Taiwan
National Health Insurance claims database.
Results
A total of 10,190 insulin glargine initiators and 49,253
intermediate/long-acting HI initiators were included in the
analysis (Figure 1). These two treatment groups differed in many
baseline characteristics (Table 1). As compared with intermediate/
long-acting HI initiators, those who starting insulin glargine
therapy were more likely to have history of ketoacidosis or non-
ketotic hyperosmolarity and retinopathy, but less likely to have
cerebrovascular and peripheral vascular diseases, nephropathy,
chronic kidney and lung disease; were mostly cared for by
endocrinologists and in the medical centers. A significantly higher
proportion of insulin glargine initiators also received oral anti-
diabetic agents and statins, while less received fast-acting insulin
therapy during the 6-month period prior to the initiation of insulin
glargine. Insulin glargine initiators received more frequent
hemoglobin A1C measurements and have more frequent outpa-
tient visits due to diabetes but less likely to be hospitalized due to
either diabetes or non-diabetes problems.
‘‘Exclusive users’’ analysis
The average follow-up duration for insulin glargine initiators
was 526 days, shorter than 745 days for intermediate/long-acting
HI initiators (Table 2). Insulin glargine initiators were more likely
to use oral anti-diabetic agents, metformin, and sulfonylurea
whereas intermediate/long-acting HI initiators more often used
fast-acting insulins as concomitant medications. The mean daily
dosage of studied insulin was 0.48 DDD (19.2 IU/day) for glargine
users as compared with 0.41 DDD (16.4 IU/day) for intermedi-
ate/long-acting HI users. In addition, the mean daily dosage for all
anti-diabetic agents, including sulfonylurea (1.26 vs. 0.98 DDD)
and metformin (0.59 vs. 0.47 DDD) among users were higher in
insulin glargine initiators.
A total of 179 cancer cases in the insulin glargine initiators and
1,445 cancer cases in the intermediate/long-acting HI initiators
occurred during follow-up. The crude incidence rate of all cancers
per 1,000 person-year was 13.8 (95% CI: 11.7–15.8) for insulin
glargine initiators and 16.0 (95% CI: 15.2–16.8) for intermediate/
long-acting HI initiators (Table 3). No significantly increased risk
of cancer was found for insulin glargine initiators as compared
with intermediate/long-acting HI initiators. The crude hazard
ratio for any cancer was 0.84 (95% CI: 0.72–0.98); the hazard
ratio was 0.86 (95% CI: 0.72–1.01) after adjusting for baseline
propensity score. Results were similar in the traditional multivar-
iable-adjusted model and extended Cox model controlling for
baseline propensity score, time-varying anti-diabetic medication
use, and mean daily dosage of studied insulin during the study
period (Table 4). For individual sites of cancer, a significantly
increased risk was found for pancreatic cancer, particularly in
men. The adjusted hazard ratio was 2.15 (95% CI 1.01–4.59) for
pancreatic cancer, and 2.42 (95% CI 1.50–8.40) for prostate
cancer (Table 4 and Table 5). The increased risk was not observed
among women (Table 5).
In the analyses stratified on different dose and duration
categories, we found no significant difference in the risk of overall
cancer between insulin glargine initiators and HI initiators, among
those with higher cumulative dose (.300 DDD), higher mean
daily dosage ($0.5 DDD/day) or longer cumulative treatment
duration ($1 years) (Table 6). Relatively few patients had
pancreatic and prostate cancer in each dose and duration
categories and the confidence intervals were wide. However,
insulin glargine was potentially associated with a significantly
increased risk of pancreatic cancer with cumulative dosage $300
DDD; the adjusted hazard ratio was 7.75 (95% CI: 2.64–22.72).
No significantly excess risk was found for prostate cancer in
different dose- and duration categories.
‘‘As-treated’’ analysis
In this analysis, we followed all studied insulin users to the
earliest of cancer diagnosis, death, disenrollment, discontinuing
studied insulin or switching to another insulin, or study end. The
average follow-up duration was 238 days for insulin glargine
initiators and 205 days for intermediate/long-acting HI initiators.
A total of 78 cancer cases in the insulin glargine initiators and
390 cancer cases in the intermediate/long-acting HI initiators
occurred during follow-up. The crude incidence rate of all cancers
per 1,000 person-year was 11.7 (95% CI: 9.1–14.3) for insulin
glargine initiators and 14.1 (95% CI: 12.7–15.5) for intermediate/
long-acting HI initiators. No significantly increased risk of cancer
was found for insulin glargine initiators as compared with
intermediate/long-acting HI initiators. The crude hazard ratio
for any cancer was 0.83 (95% CI: 0.65–1.06); the hazard ratio was
0.81 (95% CI: 0.62–1.05) after adjusting for baseline propensity
score. Similarly, a significantly increased risk was found among
men with the adjusted hazard ratio of 3.38 (95% CI 1.18–9.66) for
pancreatic cancer, and 4.44 (95% CI 1.12–17.68) for prostate
cancer (Supplementary Tables S2 and S3).
In the analyses stratified on different dose and duration
categories, we found no significant difference in the risk of overall
cancer between insulin glargine initiators and HI initiators,
although relatively few patients had pancreatic and prostate
cancer in each dose and duration categories and the confidence
intervals were wide (Supplementary Table S4).
Analysis using age as timescale in the Cox model
Results were similar between the analysis using age as the
timescale and that using time since starting insulin in the Cox
model (Table 7). A significantly higher risk associated with insulin
glargine use was also found for pancreatic cancer, particularly in
men, and for prostate cancer.
Discussion
In a Chinese population with high incidence of colorectal, liver,
and lung cancers, insulin glargine was not associated with an
excess risk of overall cancer as compared to intermediate/long-
acting HI among adult type 2 diabetes patients over an average
follow-up of 2 years. This result is consistent with the finding from
Insulin Glargine and Cancer Risk
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patients comparing insulin glargine with neutral protamine
Hagedorn insulin [4]. In that study patients were followed for 5
years and no difference in cancer risk was observed. However, a
potentially increased risk of pancreatic and prostate cancer was
found in our study which required further investigations for
confirmation.
Evidence suggests a direct link between serum insulin and
elevated blood glucose levels and several cancer sites [13,14].
Therefore, confounding by underlying diabetes severity or other
risk factors for cancer deserves special attention [11]. The
incomparability between insulin glargine users and other types
of insulin or oral anti-diabetic agent users raises the question about
the most appropriate reference group in the studies of cancer risk
and insulin. In Taiwan, insulin glargine has been recommended to
be used among patients with poor controlled diabetes or frequent
episodes of hypoglycemia. In this study intermediate/long-acting
HI was selected as the comparison group because both were used
Figure 1. Study flow.
doi:10.1371/journal.pone.0021368.g001
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human insulin (HI).
Insulin glargine initiators
(N=10,190)
HI initiators
(N=49,253)
Standardized mean difference/
Odds ratio (95% CI)
Patient characteristics
Age at studied insulin initiation (mean 6 SD) 60.65612.84 62.07613.41 20.08
#34 2.5 3.0 Reference
35–44 8.3 7.3 1.38 (1.18, 1.60)
45–54 21.2 18.4 1.38 (1.20, 1.59)
55–64 27.7 25.2 1.32 (1.15, 1.52)
$65 40.3 46.1 1.05 (0.92, 1.21)
Male (%) 49.5 47.7 1.08 (1.03, 1.12)
Initiation year (%)
2004 7.3 32.6 Reference
2005 20.9 31.8 2.94 (2.70, 3.20)
2006 41.8 25.1 7.43 (6.85, 8.06)
2007 30.0 10.6 12.61 (11.57, 13.75)
Diabetes-related late complications (%)
Cardiovascular disease 66.9 66.4 1.02 (0.97, 1.07)
Ischemic heart disease 19.2 20.3 0.93 (0.89, 0.99)
Peripheral vascular disease 2.2 2.8 0.79 (0.69, 0.91)
Cerebrovascular disease 12.6 17.1 0.70 (0.66, 0.74)
Ketoacidosis or hyperosmolarity 24.6 17.8 1.51 (1.43, 1.59)
Retinopathy 33.2 30.3 1.14 (1.09, 1.20)
Neuropathy 22.7 21.7 1.06 (1.01, 1.11)
Nephropathy 36.5 40.6 0.84 (0.81, 0.88)
Chronic kidney disease 8.1 11.1 0.71 (0.66, 0.76)
Chronic liver disease 13.5 13.5 1.00 (0.94, 1.07)
Chronic lung disease 9.1 14.1 0.61 (0.57, 0.66)
Depression 2.7 2.8 0.94 (0.82, 1.07)
Charlson’s index (not include diabetes) $1 47.2 54.5 0.75 (0.72, 0.78)
Medication use (%)
Biguanides 76.0 62.1 1.93 (1.83, 2.02)
Sulfonylurea 79.3 67.8 1.82 (1.73, 1.92)
Alpha-glucosidase inhibitors 36.6 22.5 1.99 (1.91, 2.09)
Thiazolidinediones 43.5 25.9 2.21 (2.11, 2.31)
Glinides 17.4 14.4 1.26 (1.19, 1.33)
Any oral anti-diabetic agents 92.0 79.2 3.03 (2.81, 3.26)
Fast-acting insulins 28.5 42.0 0.55 (0.53, 0.58)
Premixed insulin 20.8 19.7 1.07 (1.02, 1.13)
Insulin detemir 1.4 0.2 6.40 (4.97, 8.25)
Statins 36.3 27.1 1.54 (1.47, 1.61)
Aspirin 34.4 33.2 1.06 (1.01, 1.11)
Resource utilization (%))
Number of A1C measurement 10.966.1 8.765.9 0.03
0 16.4 36.0 Reference
1–2 31.7 29.4 2.36 (2.22, 2.51)
3–4 32.6 23.4 3.06 (2.87, 3.26)
.4 19.2 11.2 3.76 (3.49, 4.04)
Number of outpatient visits due to diabetes 8.364.7 7.465.2 20.10
0–5 34.9 43.2 Reference
6–10 47.4 40.6 1.45 (1.38, 1.52)
Insulin Glargine and Cancer Risk
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still significant differences in the baseline characteristics, including
comorbidities, diabetic complications, and other medications
between the two groups. Our analyses adjusted for these baseline
imbalances between insulin glargine and intermediate/long-acting
HI initiators, but we could not rule out the possibility of residual
confounding.
Additionally, insulin glargine group had a higher mean daily
dosage of sulfonylurea and metformin concomitantly after
treatment initiation. In contrast to a German study that an excess
cancer risk with insulin glargine emerged after adjustment for dose
[6], our risk estimates for overall cancer and individual sites of
cancer did not change substantially after adjusting for insulin
dosage. In this study, we used an extended Cox model to adjust for
time-varying covariates. Other more sophisticated approaches,
including marginal structural model, might provide less biased
estimates [15].
Other potential bias that may explain an association between
insulin glargine use and cancer include reverse causation – cancer
may affect glycemic control (manifest as either hyper- or
hypoglycemia) that leads physicians to switch to insulin glargine
[11]. Analysis including only ‘‘exclusive users’’, although reduce
the biases from exposure misclassification which may bias effects
toward the null, on the other hand, may be open to bias due to
informative censoring [16]. Therefore, we conducted additional
analysis using a ‘‘new-user design’’ that required patients who did
not have a history of cancer to be free of any studied insulin use
during the 6-month period preceding the start of insulin treatment
and censored patients when they stopped using glargine insulin or
intermediate/long-acting HI or started using another study insulin
[17]. Despite this design allowed us to estimate the incidence of
cancer following a new episode of insulin treatment, follow-up
duration was substantially shorter as compared with analysis on
exclusive users which led to imprecise risk estimates. A nested case-
control design comparing cumulative exposure of insulin glargine
and intermediate/long-acting HI between cancer cases and time-
matched control may analyze the data more efficiently.
Despite no excess of overall cancer incidence, our study showed
that insulin glargine might be associated with a higher chance of
pancreatic cancer and prostate cancer diagnosis. Due to few
number of cancer cases, we could not evaluate the potential dose
and duration of insulin glargine use that increased the occurrence
of these two cancers. The mechanisms leading to this positive
association was uncertain, as pancreatic cancer cells were
Insulin glargine initiators
(N=10,190)
HI initiators
(N=49,253)
Standardized mean difference/
Odds ratio (95% CI)
.10 17.7 16.2 1.35 (1.27, 1.43)
Number of outpatient visits not due to diabetes
0–10 61.6 55.4 Reference
11–20 23.9 26.5 0.81 (0.77, 0.85)
.20 14.6 18.1 0.73 (0.68, 0.77)
Emergency department visit 27.0 32.2 0.78 (0.74, 0.82)
Gastrointestinal specialist 12.9 13.3 0.96 (0.90, 1.03)
Urology specialist 8.0 8.0 1.01 (0.93, 1.09)
Chest medicine physicians 6.1 7.4 0.81 (0.74, 0.88)
Abdominal sonographic examination 11.7 11.9 0.99 (0.92, 1.05)
Colonoscopic examinations 0.1 0.1 0.86 (0.45, 1.63)
Mammographic examinations 0.8 0.6 1.34 (1.05, 1.72)
Serum prostate specific antigen measurement 1.9 1.6 1.16 (0.99, 1.36)
Chest x ray examinations 26.7 32.2 0.77 (0.73, 0.80)
Hospitalization due to diabetes 19.1 23.5 0.77 (0.73, 0.81)
Hospitalization not due to diabetes 15.0 23.2 0.58 (0.55, 0.62)
Physician characteristics
Age (mean 6 SD) 48.83615.54 47.72613.07 0.10
#34 13.1 10.0 Reference
35–44 38.2 40.7 0.72 (0.67, 0.77)
45–54 23.5 28.8 0.62 (0.58, 0.67)
55–64 8.3 7.9 0.79 (0.72, 0.87)
$65 17.0 12.6 1.03 (0.95, 1.12)
Male (%) 82.1 88.8 0.58 (0.55, 0.61)
Specialty (%)
Endocrinologist 60.2 38.0 2.43 (2.28, 2.58)
General internist 25.6 40.4 0.97 (0.90, 1.04)
Family doctor and others 14.2 21.7 Reference
SD: Standard deviation.
doi:10.1371/journal.pone.0021368.t001
Table 1. Cont.
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human insulin, and survival in insulin glargine-treated patients
after treatment for pancreatic cancer was similar to those on
human insulin [18]. However, due to the possibility that insulin
analogues may promote the growth of subclinical tumors in a
relative short duration of exposure, this potential risk deserved
attention and needed to be evaluated in further studies. Similar to
prior reports, the duration of exposure to insulin glargine in the
present study was less than what would be reasonably anticipated
for establishing a causal relationship with carcinogenicity. Taken
together, these observations suggest that the use of insulin glargine
increases the rate of development and subsequent detection of pre-
existing undetectable malignancies rather than malignant cell
transformation and new cancer formation. In contrast to a
significantly increased risk of breast cancer associated with glargine
use reported by the Swedish and the Scottish studies [8,9], our
study did not find a relation with breast cancer.
Our study has several limitations. First, we were not able to
examine the long-term effect of insulin glargine on cancer
although our average length of follow-up is comparable or slightly
longer than previous studies. Second, as discussed above, there
might be residual confounding by duration or severity of diabetes,
as well as by obesity, smoking, and physical inactivity. Due to lack
of data about the exact extent of glycemic control, we could not
examine whether hyperglycemia per se or a higher dose of insulin
glargine attributes to the association with a greater risk of certain
Table 2. Follow-up in days and medication use in exclusive users of insulin glargine compared to intermediate/long-acting human
insulin (HI).
Insulin glargine initiators
(N=9,041)
HI initiators
(N=44,274)
Follow-up days (mean 6 SD) 525.906284.57 745.366366.84
Medication use
Fast-acting insulins 1827 (20.2%) 22803 (51.5%)
Insulin detemir 677 (7.5%) 1883 (4.3%)
Any oral anti-diabetic medications 8349 (92.3%) 34291 (77.5%)
Sulfonylurea 6597 (73.0%) 27604 (62.3%)
Metformin 6310 (69.8%) 27034 (61.1%)
Daily dosage in DDD among users (mean 6 SD)
Studied insulin 0.4860.48 0.4160.65
Fast-acting insulin 0.3060.53 0.3060.85
Insulin detemir 0.1960.18 0.1460.16
Any oral anti-diabetic medications 1.8161.28 1.4061.21
Sulfonylurea 1.2661.01 0.9860.87
Metformin 0.5960.38 0.4760.37
SD: Standard deviation.
doi:10.1371/journal.pone.0021368.t002
Table 3. Crude incidence rate of any cancer and individual site of cancer among exclusive users of insulin glargine vs.
intermediate/long-acting human insulin (HI).
Insulin glargine initiators
(Total follow-up 13017.6 person-years)
HI initiators
(Total follow-up 90349.0 person-years)
Number of cases
Incidence rate per 1,000 person-years
(95% confidence interval) Number of cases
Incidence rate per 1,000 person-years
(95% confidence interval)
Any cancer 179 13.8 (11.7, 15.8) 1445 16.0 (15.2, 16.8)
Breast
a 6 0.9 (0.2, 1.6) 65 1.4 (1.0, 1.7)
Colorectal 23 1.8 (1.0, 2.5) 205 2.3 (2.0, 2.6)
Stomach 7 0.5 (0.1, 0.9) 79 0.9 (0.7, 1.1)
Pancreas 23 1.8 (1.0, 2.5) 73 0.8 (0.6, 1.0)
Liver 42 3.2 (2.3, 4.2) 405 4.5 (4.0, 4.9)
Lung 19 1.5 (0.8, 2.1) 137 1.5 (1.3, 1.8)
Prostate
b 9 1.4 (0.5, 2.3) 29 0.7 (0.4, 0.9)
Kidney and urinary bladder 8 0.6 (0.2, 1.0) 98 1.1 (0.9, 1.3)
Skin 8 0.6 (0.2, 1.0) 54 0.6 (0.4, 0.8)
aTotal follow-up person-year for women: 6,558.8 for insulin glargine users and 47,724.6 for HI users.
bTotal follow-up person-year for men: 6,458.8 for insulin glargine users and 42,624.4 for HI users.
doi:10.1371/journal.pone.0021368.t003
Insulin Glargine and Cancer Risk
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izations among insulin glargine users might have led to more
cancer cases being detected in these patients. However, if there
was a detection bias, we would expect to see a similarly increased
risk for individual sites cancers, including breast, colorectal and
liver cancer. And finally, we could not exclude the possibility that
some of the associations might be due to chance, as multiple
individual sites of cancer were examined simultaneously.
Table 4. Hazard ratio of overall and individual cancer among exclusive users of insulin glargine vs. intermediate/long-acting
human insulin (HI) users.
Unadjusted
Traditional
multivariable
adjusted
a
Adjusted for baseline
propensity score
Adjusted for baseline
propensity score and
time-varying
medication use
b
Adjusted for baseline
propensity score, time-
varying medication
use and dosage of
studied insulin
Any cancer 0.84
(0.72, 0.98)
0.86
(0.73, 1.01)
0.86
(0.72, 1.01)
0.85
(0.72, 1.01)
0.86
(0.73, 1.02)
Breast (women) 0.71
(0.31, 1.65)
0.62
(0.25, 1.51)
0.56
(0.23, 1.36)
0.55
(0.22, 1.35)
0.53
(0.21, 1.31)
Colorectal 0.79
(0.51, 1.22)
0.86
(0.54, 1.36)
0.85
(0.53, 1.35)
0.80
(0.5, 1.28)
0.78
(0.49, 1.26)
Stomach 0.60
(0.27, 1.30)
0.65
(0.28, 1.47)
0.59
(0.26, 1.35)
0.63
(0.27, 1.44)
0.62
(0.27, 1.42)
Pancreas 1.89
(1.17, 3.03)
1.69
(0.99, 2.87)
1.83
(1.07, 3.12)
1.88
(1.08, 3.27)
1.85
(1.06, 3.22)
Liver 0.70
(0.51, 0.97)
0.74
(0.53, 1.04)
0.74
(0.53, 1.04)
0.74
(0.52, 1.04)
0.76
(0.54, 1.08)
Lung 0.97
(0.60, 1.57)
0.97
(0.58, 1.63)
0.98
(0.58, 1.64)
0.98
(0.58, 1.66)
1.01
(0.59, 1.71)
Prostate (men) 2.01
(0.94, 4.29)
2.27
(0.94, 5.48)
2.42
(1.50, 8.40)
2.42
(0.96, 6.09)
2.37
(0.94, 6.01)
Kidney and urinary bladder 0.54
(0.26, 1.12)
0.59
(0.27, 1.26)
0.60
(0.28, 1.29)
0.53
(0.25, 1.15)
0.54
(0.25, 1.16)
Skin 1.06
(0.50, 2.24)
1.14
(0.51, 2.57)
1.18
(0.53, 2.64)
1.17
(0.52, 2.64)
1.08
(0.48, 2.46)
aAdjusted for all variables in Table 1.
bTime-varying medication use included insulin detemir (binary), mean daily dosage of fast-acting insulins, sulfonylurea, and metformin (in quartiles).
doi:10.1371/journal.pone.0021368.t004
Table 5. Hazard ratio of overall and individual cancer comparing exclusive use of insulin glargine with intermediate/long-acting
human insulin (HI) among men and women.
Women Men
Unadjusted
Adjusted for baseline
propensity score Unadjusted
Adjusted for baseline
propensity score
Any cancer 0.78
(0.61, 1.00)
0.71
(0.55, 0.92)
0.87
(0.71, 1.07)
0.97
(0.78, 1.22)
Colorectal 0.89
(0.49, 1.63)
0.78
(0.41, 1.51)
0.70
(0.37, 1.30)
0.92
(0.47, 1.80)
Stomach 0.75
(0.23, 2.47)
0.64
(0.18, 2.31)
0.50
(0.18, 1.40)
0.59
(0.20, 1.72)
Pancreas 2.00
(1.01, 3.96)
1.43
(0.66, 3.11)
1.78
(0.92, 3.42)
2.15
(1.01, 4.59)
Liver 0.56
(0.32, 0.98)
0.53
(0.29, 0.96)
0.78
(0.53, 1.15)
0.84
(0.55, 1.29)
Lung 0.87
(0.37, 2.05)
0.84
(0.33, 2.12)
0.99
(0.55, 1.79)
1.03
(0.55, 1.95)
Kidney and urinary bladder 0.53
(0.19, 1.48)
0.64
(0.22, 1.91)
0.55
(0.20, 1.53)
0.48
(0.16, 1.42)
Skin 0.71
(0.22, 2.34)
0.71
(0.20, 2 .55)
1.52
(0.57, 4.08)
1.74
(0.60, 5.07)
doi:10.1371/journal.pone.0021368.t005
Insulin Glargine and Cancer Risk
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21368In conclusion, we did not find an increased risk of overall cancer
incidence associated with insulin glargine use among type 2
diabetes patients. The positive associations between insulin
glargine and pancreatic and prostate cancer definitely require
further investigations.
Materials and Methods
Ethics
The National Taiwan University Hospital Research Ethics
Committee approved the protocol of this study and waived the
Table 6. Hazard ratio of overall cancer and pancreatic cancer among exclusive users of insulin glargine vs. intermediate/long-
acting human insulin (HI) users.
Hazard Ratio (95% CI)
Crude
Adjusted for baseline propensity
score
a
Adjusted for baseline propensity score
and time-varying medication use
b
Overall cancer
Cumulative dosage
.300 DDD 1.05 (0.77, 1.43) 1.17 (0.83, 1.64) 1.18 (0.83, 1.67)
50–135 DDD 0.70 (0.49, 0.98) 0.77 (0.53, 1.12) 0.79 (0.54, 1.16)
135–300 DDD 0.69 (0.48, 0.98) 0.74 (0.50, 1.09) 0.75 (0.50, 1.11)
,50 DDD 0.90 (0.69, 1.18) 0.82 (0.61, 1.09) 0.81 (0.6, 1.07)
Cumulative duration
$1 years 0.86 (0.60, 1.23) 0.88 (0.59, 1.31) 0.91 (0.61, 1.36)
,1 years 0.82 (0.69, 0.98) 0.83 (0.69, 1.01) 0.83 (0.69, 1.01)
Mean daily dosage
$0.5 DDD/day 1.04 (0.84, 1.28) 1.06 (0.85, 1.33) 1.05 (0.84, 1.32)
,0.5 DDD/day 0.65 (0.51, 0.83) 0.65 (0.50, 0.85) 0.68 (0.52, 0.89)
Pancreatic cancer
Cumulative dosage
.300 DDD 4.28 (1.68, 10.88) 7.75 (2.64, 22.72) 7.90 (2.64, 23.71)
135–300 DDD 0.97 (0.28, 3.40) 1.12 (0.26, 4.80) 1.15 (0.27, 5.00)
50–135 DDD 1.11 (0.37, 3.34) 1.27 (0.37, 4.36) 1.19 (0.34, 4.17)
,50 DDD 2.05 (0.96, 4.38) 1.18 (0.51, 2.72) 1.23 (0.53, 2.84)
Cumulative duration
$1 years 1.27 (0.28, 5.71) 2.28 (0.44, 11.78) 2.58 (0.50, 13.23)
,1 years 1.94 (1.17, 3.19) 1.70 (0.96, 3.01) 1.75 (0.98, 3.12)
Mean daily dosage
$0.5 DDD/day 2.20 (1.12, 4.33) 1.85 (0.87, 3.94) 1.84 (0.86, 3.95)
,0.5 DDD/day 1.61 (0.83, 3.12) 1.78 (0.81, 3.94) 1.92 (0.85, 4.32)
Prostate cancer (men)
Cumulative dosage
.300 DDD 2.20 (0.45, 10.72) 1.73 (0.28, 10.68) 2.16 (0.33, 14.10)
135–300 DDD 3.07 (0.68, 13.80) 5.28 (0.73, 37.93) 5.37 (0.71, 40.85)
50–135 DDD 2.31 (0.41, 12.94) 1.69 (0.26, 10.88) 2.06 (0.29, 14.7)
,50 DDD 1.07 (0.24, 4.87) 2.03 (0.33, 12.38) 1.88 (0.30, 11.63)
Cumulative dosage
$180 DDD 2.66 (0.80, 8.82) 2.02 (0.47, 8.71) 2.39 (0.53, 10.76)
,180 DDD 1.55 (0.57, 4.20) 2.46 (0.77, 7.92) 2.38 (0.73, 7.78)
Cumulative duration
$1 years 1.85 (0.37, 9.18) 1.65 (0.26, 10.44) 1.79 (0.26, 12.33)
,1 years 1.93 (0.81, 4.58) 2.61 (0.92, 7.44) 2.52 (0.87, 7.25)
Mean daily dosage
$0.5 DDD/day 1.55 (0.44, 5.41) 1.91 (0.46, 7.91) 1.98 (0.47, 8.40)
,0.5 DDD/day 2.21 (0.83, 5.87) 2.83 (0.84, 9.54) 2.95 (0.83, 10.43)
aExtended Cox model with time-varying insulin glargine and HI use, controlling for baseline propensity score.
bExtended Cox model with time-varying insulin glargine and HI use, controlling for baseline propensity score and time-varying use of insulin detemir (binary), mean
daily dosage of fast-acting insulins, sulfonylurea, and metformin (in quartiles).
doi:10.1371/journal.pone.0021368.t006
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study based on data from administrative databases and involved
only minimal risk.
Data Source
The Taiwan National Health Insurance database includes
complete outpatient visits, hospital admissions, diagnoses, pre-
scriptions, disease and vital status for 99% of the population (about
23 million) in Taiwan. We established a longitudinal medical
history of each beneficiary by linking the computerized adminis-
trative and claims datasets, and the National Cancer and Death
Registry through the civil identification number unique to each
beneficiary and date of birth. Our source population comprised all
beneficiaries aged $18 years between January 1, 2004 and
December 31, 2007.
Study Population
From the source population, we identified beneficiaries with a
first prescription of either insulin glargine (anatomical therapeutic
chemical [ATC] classification system code A10AE04) or interme-
diate/long-acting HI (ATC codes A10AC01 and A10AE01)
between July 1, 2004 and June 30, 2007 (insulin glargine entered
Taiwan’s market in 2004). We refer to the date of first prescription
of either insulin therapy as the index date. We required eligible
beneficiaries to have no prescription of either insulin glargine or
intermediate/long-acting HI in the 6 months preceding the index
date. Intermediate/long-acting HI was used as the active
comparator for insulin glargine because both were used as
alternatives for basal insulin supplement and we expected the
characteristics between two treatment groups to be more similar as
compared with other types of insulin or analogues.
To exclude patients with potential type 1 diabetes, we excluded
those who 1) had a hospital admission with a discharge diagnosis of
insulin dependent diabetes mellitus (International Classification of
Diseases, 9
th Revision, Clinical Modification [ICD-9-CM] codes
250.x1, 250.x3), or 2) received a catastrophic illness certificate
issued by the Department of Health for type 1 diabetes. We further
excluded patients who 1) did not have continuous insurance
coverage 6 months preceding the index date, 2) had a history of
cancer recorded in the National Cancer Registry anytime before
the index date, and 3) received both insulin glargine and
intermediate/long-acting HI on the index date.
The primary outcome of this study was any cancer, and the
secondary outcomes were specific site of cancer, including liver,
colorectal, pancreatic, lung, kidney or urinary bladder, stomach,
skin, breast, and prostate cancer. All of the cancer occurrences
were identified and validated by linkage through the National
Cancer Registry. National Cancer Registry in Taiwan was
launched in 1979 to collect information of all incident cancer
cases from hospitals with 50 or more beds. It was considered a
complete and accurate registry with a percentage of cases based on
death certificate only as low as 3.9% in 2000 and 1.8% in 2005.
Covariate Ascertainment and Adjustment
We used inpatient and outpatient diagnosis files and prescrip-
tion file during the 6-month period before the index date to
ascertain patients’ history of cardiovascular, peripheral vascular,
cerebrovascular disease, metabolic derangement (diabetes with
ketoacidosis, hyperosmolarity, and with other coma), retinopathy,
nephropathy, neuropathy, and depression (ICD-9-CM codes
provided in Supplementary Table S1); and use of biguanides
(A10BA), sulfonylurea (A10BB), alpha-glucosidase inhibitors
(A10BF), thiazolidinediones (A10BG), glinides (A10BX02,
A10BX03), detemir insulin (A10AE05), fast-acting insulins and
analogues (A10AB), low-dose aspirin (B01AC06), and statins
(C10AA). Using these covariates plus age (in five categories), sex,
studied insulin initiation year (1-year band), physicians’ charac-
teristics and patients’ health services utilization (number of
outpatient visits, number of hospitalizations, use of preventive
medicine services) in the 6 months preceding the index date, we
estimated the propensity score – the probability of initiating insulin
glargine – with a logistic regression model.
For use of other types of insulin and oral anti-diabetic agents, we
further identified date of prescription, days supplied, and total
amount prescribed. For each patient we estimated mean daily dose
by calculating cumulative dose prescribed divided by the total
follow-up duration at risk. Data were presented as the number of
defined daily doses (DDD) which was established by an expert
panel as the typical maintenance dose required when the drug is
used for its main indication in an adult [19].
Table 7. Hazard ratio of overall and individual cancer comparing exclusive users of insulin glargine vs. intermediate/long-acting
human insulin (HI) using age as timescale in the Cox proportional hazard model.
Using age as timescale,
unadjusted
Using age as timescale and
stratified on birth cohort,
unadjusted
Using age as time scale and stratified
on birth cohort, adjusted for baseline
propensity score
Any cancer 0.91 (0.78, 1.06) 0.91 (0.78, 1.06) 0.86 (0.72, 1.02)
Breast (women) 0.68 (0.29, 1.57) 0.65 (0.28, 1.51) 0.56 (0.23, 1.37)
Colorectal 0.85 (0.55, 1.31) 0.86 (0.56, 1.33) 0.86 (0.54, 1.38)
Stomach 0.70 (0.32, 1.52) 0.71 (0.33, 1.53) 0.63 (0.28, 1.44)
Pancreas 2.31 (1.44, 3.69) 2.26 (1.41, 3.63) 1.81 (1.05, 3.11)
Pancreas (men) 2.13 (1.11, 4.08) 2.07 (1.07, 3.98) 2.20 (1.04, 4.69)
Liver 0.74 (0.53, 1.01) 0.73 (0.53, 1.01) 0.72 (0.51, 1.01)
Lung 1.08 (0.67, 1.74) 1.07 (0.66, 1.73) 0.98 (0.58, 1.66)
Prostate (men) 2.28 (1.08, 4.83) 2.39 (1.12, 5.09) 2.59 (1.04, 6.45)
Kidney and urinary bladder 0.64 (0.31, 1.31) 0.63 (0.31, 1.29) 0.56 (0.26, 1.21)
Skin 1.17 (0.56, 2.46) 1.17 (0.56, 2.47) 1.15 (0.51, 2.58)
doi:10.1371/journal.pone.0021368.t007
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Baseline characteristics, comorbidities, medication use, and
health services utilization related to starting insulin glargine rather
than intermediate/long-acting HI therapy were identified by
calculating odds ratios and their 95% CIs from a Logistic
regression model. We estimated the incidence rate and its 95%
confidence interval (CI) of overall cancer and specific site of cancer
based on a Poisson distribution.
In the ‘‘exclusive users’’ analysis, we restricted to patients who
used insulin glargine or HI but not both during the whole study
period and following them to the earliest of cancer diagnosis, death,
disenrollment, or December 31 2007. We estimated the hazard
ratio and its 95% CI of all cancer and individual site of cancer
comparing insulin glargine initiators with intermediate/long-acting
HI initiators by fitting five different Cox proportional hazards
models: 1) unadjusted, 2) adjusted for all baseline variables in
Table 1 by a traditional multivariable model, 3) adjusted for
baseline propensity score in deciles, 4) adjusted for baseline
propensity score and time-varying use of insulin detemir, mean
daily dosage of fast-acting insulin, sulfonylurea, and metformin use
in quartiles after the index date, and 5) adjusted for baseline
propensity score, time-varying use of insulin detemir, mean daily
dosage of fast-acting insulin, sulfonylurea, and metformin use in
quartiles, and time-varying mean daily dosage of insulin glargine or
intermediate/long-acting HI ($0.5 DDD/day and ,0.5 DDD/
day). These hypoglycemic agents and insulin glargine dosage have
been reported to be associated with cancer risks and could
potentially confound the risk estimates between two treatment
groups. Analyses adjusted for baseline propensity score were further
stratified by men and women to see if there was any treatment by
gender interaction. We tested the proportional hazards assumption
by including a treatment-by-time interaction term.
We also conducted additional analyses that 1) followed all
studied insulin users based on their treatment status on the index
date to the earliest of cancer diagnosis, death, disenrollment,
discontinuing studied insulin or switching to another insulin, or
study end (‘‘as-treated analysis’’), and 2) using age as the timescale
(i.e. with the same entry and exit dates for each person but
declaring date of birth as the origin) in the Cox model while
stratifying by birth cohort (10-year intervals) for a better control of
age and calendar effects (‘‘age as the timescale’’). In addition, we
classified exposure person-days of studied insulin use into
cumulative dose (in quartiles); cumulative duration $1 and ,1
year; and mean daily dosage $0.5 DDD/day and ,0.5DDD/
day; and calculated the hazard ratios of insulin glargine use vs. HI
use for each category. Potential dose and duration response were
explored when an association with specific cancer site was found.
All statistical analyses were performed with SAS 9.2 (SAS
Institute, Cary, NC).
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